Since Hippo pathway deficiency can induce cancer addiction to YAP43,46–48, the identified Hippo LOF mutations could be used as genomic biomarkers and developed as a “toolset” to predict YAP activation and guide the application of YAP/TAZ/TEAD-based compounds for personalized cancer therapy. This evidence concerns the gene YAP1 and cancer.